Allogene Therapeutics Stock Price, News & Analysis

Allogene Therapeutics (NASDAQ: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its participation in four major investor conferences:

• TD Cowen's 6th Annual Oncology Innovation Summit (May 27, 9:30AM PT)
• Jefferies Global Healthcare Conference (June 4, 1:55PM PT)
• Goldman Sachs 46th Annual Global Healthcare Conference (June 10, 5:00AM PT)
• Oppenheimer Innovators in I&I Summit (June 25, 9:45AM PT)

Webcasts of the presentations will be available on the company's website (www.allogene.com) under the Investors tab, with replays accessible for approximately 30 days after the events.

Allogene Therapeutics (NASDAQ: ALLO) announced two key presentations at the upcoming 2025 ASCO Annual Meeting. The first is an oral presentation featuring ALLO-316, their investigational AlloCAR T product targeting CD70 for advanced renal cell carcinoma (RCC). ALLO-316, utilizing the proprietary Dagger® technology, is notable as the first allogeneic CAR T product showing promise in solid tumors. The presentation will include updated data from the Phase 1 TRAVERSE study's expansion cohort.

Additionally, a Trial-in-Progress poster will showcase the Phase 2 ALPHA3 trial design for cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma (LBCL). This trial evaluates cema-cel as a first-line consolidation treatment for patients who remain minimal residual disease (MRD) positive after initial chemoimmunotherapy.

The pivotal Phase 2 ALPHA3 trial for Cema-Cel in LBCL has nearly 50 activated sites across the U.S., with over 250 patients consented for MRD screening. However, the lymphodepletion selection and futility analysis has been delayed to 1H 2026 due to site-related factors.

The company implemented cost-realignment measures to extend cash runway into 2H 2027, focusing on advancing Cema-Cel/ALPHA3 and ALLO-329/RESOLUTION trials. The RESOLUTION trial for autoimmune diseases is set to begin mid-2025, while updated Phase 1 ALLO-316 trial results in renal cell carcinoma will be presented at ASCO 2025.

2025 guidance projects a decrease in cash of approximately $150 million with GAAP operating expenses around $230 million.

Allogene Therapeutics (NASDAQ: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has scheduled its Q1 2025 financial results announcement and business update for May 13, 2025, after market close. The company will host a conference call and webcast at 2:00 PM PT/5:00 PM ET on the same day.

Interested parties can access the listen-only webcast through Allogene's website (www.allogene.com) under the Investors tab. A replay will be available for approximately 30 days. Those wishing to participate in the Q&A session during the conference call must register separately to receive a personal PIN for access.

Allogene Therapeutics (NASDAQ: ALLO) will present updated data from two significant clinical trials at the 2025 ASCO Annual Meeting. The first presentation features results from the completed Phase 1 TRAVERSE trial of ALLO-316, their allogeneic CAR T product targeting CD70 in renal cell carcinoma (RCC). Previous data showed promising safety and anti-tumor activity in heavily pretreated patients with advanced CD70+ RCC.

The second presentation highlights their ongoing pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma (LBCL). This groundbreaking study is the first to evaluate an allogeneic CAR T product as first-line consolidation treatment. The randomized trial will enroll approximately 240 patients and aims to improve event-free survival compared to standard care.

Allogene Therapeutics (ALLO) has received three FDA Fast Track Designations for ALLO-329, a next-generation dual-targeted CD19/CD70 allogeneic CAR T therapy. The designations cover treatments for systemic lupus erythematous (SLE), idiopathic inflammatory myopathy (IIM), and diffuse systemic sclerosis (SSc).

The company plans to initiate the Phase 1 RESOLUTION basket trial in mid-2025, with initial proof-of-concept expected by year-end 2025. The trial will evaluate ALLO-329's safety and preliminary efficacy using the proprietary Dagger® technology, which aims to reduce or eliminate lymphodepletion requirements. The study includes two lymphodepletion arms: one using cyclophosphamide alone and another without lymphodepletion.

Allogene Therapeutics (NASDAQ: ALLO) has provided Q4 and full year 2024 financial results and corporate updates. The company reported key developments across its pipeline:

Their lead program Cemacabtagene Ansegedleucel (Cema-Cel) is advancing in the pivotal Phase 2 ALPHA3 trial for first-line Large B-Cell Lymphoma, with 40 sites activated. A lymphodepletion analysis is expected mid-2025, with primary EFS data around year-end 2026.

The FDA cleared ALLO-329's IND for autoimmune diseases, with trial initiation planned for mid-2025. ALLO-316 for renal cell carcinoma completed Phase 1b enrollment with data expected mid-2025.

Financial highlights: Q4 2024 net loss was $59.9 million ($0.28 per share). Full year 2024 net loss was $257.6 million ($1.32 per share). Cash position stands at $373.1 million as of December 31, 2024, with runway into second half of 2026.

Allogene Therapeutics (ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune disease, has scheduled its fourth quarter and full year 2024 financial results announcement for March 13, 2025, after market close.

The company will host a conference call and webcast at 2:00 PM PT/5:00 PM ET on the same day. Investors can access the listen-only webcast through Allogene's website, with a replay available for approximately 30 days. Those wishing to participate in the Q&A session must register separately to receive a personal PIN for call access.

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 8:20 AM PT/11:50 AM ET.

The company will make webcasts available on their website www.allogene.com under the Investors tab, with replays accessible for approximately 30 days after the event.